Compare RYOJ & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYOJ | PDSB |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.8M | 46.0M |
| IPO Year | 2025 | N/A |
| Metric | RYOJ | PDSB |
|---|---|---|
| Price | $4.03 | $0.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 71.7K | ★ 965.2K |
| Earning Date | 12-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.91 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $11,576,848.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.25 | ★ N/A |
| Revenue Growth | ★ 5.60 | N/A |
| 52 Week Low | $1.81 | $0.70 |
| 52 Week High | $11.43 | $2.28 |
| Indicator | RYOJ | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.09 |
| Support Level | N/A | $0.70 |
| Resistance Level | N/A | $0.94 |
| Average True Range (ATR) | 0.00 | 0.07 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 71.67 |
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.